Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers

Birgitta Schmekel, Lars Borgström, Per Wollmer

Abstract
Pathophysiologica l studies have shown that the alveolocapillary transfer of small solutes is much faster in healthy smokers than in non-smokers. The effects of smoking on the pulmonary absorption of inhaled terbutaline were examined in normal subjects. Nine healthy smokers and 13 healthy non-smokers inhaled nebulised terbutaline and dry terbutaline powder on two study days. Plasma concentrations of terbutaline were measured up to 240 minutes after the inhalation. The plasma concentration of terbutaline rose much faster in smokers than in non-smokers, the mean time to peak terbutaline concentration being 17 minutes in the smokers and 50 minutes in the non-smokers. The peak plasma concentration was nearly twice as high in the smokers as in the non-smokers, being 21 mmol/l and 23 mmol/l for the dry powder inhalation and nebuliser respectively in the smokers and 12 mmol/l and 14 mmol/l in the non-smokers. It is concluded that smoking increases the rate of terbutaline absorption and the peak plasma concentration achieved. The rapid pulmonary absorption of terbutaline in smokers may affect the onset of action of the drug and the duration of its therapeutic effects.

The transfer of small water soluble molecules from the alveoli to the blood has been studied extensively during the last decade to assess the functional integrity of the alveolocapillary barrier. The radiolabelled tracer molecule technetium-99m diethylenetriamine penta-acetic acid (99mTc DTPA) is administered in aerosol form and the radioactivity monitored over the chest, to provide a measure of the pulmonary clearance of the tracer—that is, its rate of absorption from the lung. Several groups have confirmed the findings of Jones et al. that the pulmonary clearance of 99mTc DTPA is much faster in healthy smokers than in non-smoking control subjects.

The difference in absorption of inhaled 99mTc DTPA between smokers and non-smokers reflects a difference in the functioning of the alveolocapillary barrier, and this may affect the absorption of inhaled drugs. Most selective beta agonists are water soluble and they are frequently given by inhalation so that a high tissue concentration can be achieved in the lung. Differences in the rate of absorption between smokers and non-smokers may affect the time course of the therapeutic effect and may be clinically relevant. The purpose of this study was to examine the effect of smoking on the pulmonary absorption of inhaled terbutaline in normal subjects, and its relation to the pulmonary clearance of 99mTc DTPA.

Methods
SUBJECTS
We studied 22 healthy men, nine smokers and 13 non-smokers. None of the smokers had a history of chronic bronchitis. The physical characteristics of the two groups of subjects were similar (table 1). Physical examination showed nothing abnormal in any of the subjects.

SPIROMETRY
Vital capacity (VC) and forced expiratory volume in one second (FEV1) were measured with a spirometer based on a pneumotachograph (Vitalograph Compact, Vitalograph Ltd, Buckingham) as the best of three measurements. The results were related to predicted normal values.

PULMONARY CLEARANCE OF 99mTc DTPA
A solution of 99mTc DTPA was prepared from a commercially available kit (Pentetate II, Amersham International, Amersham) and nebulised with an air jet nebuliser (UltraVent, Mallinkrodt Diagnostica, Petten, The Netherlands). The mass median diameter of the particles was 1.7 μm. The subjects inhaled the aerosol by quiet tidal breathing for one to two minutes while seated in front of a gamma camera (Maxicamera 400T, General Electric Company, Milwaukee, Wisconsin) until a count rate of about 2000 counts/second had been reached. The subjects were then placed immediately in the supine position on a thin couch and the gamma camera was placed under the couch to obtain a posterior image of the lungs. The gamma camera was interfaced with a computer system and the measurements of radioactivity over the chest were stored in one minute frames for 180 minutes in a 64 × 64 image matrix. After about 170 minutes a small amount of 99mTc DTPA was injected intravenously to enable a correction for non-pulmonary radioactivity to be performed.

The measurements were analysed by selecting a region of interest that enclosed both
lungs and by generating a time-activity curve. The correction for non-pulmonary radioactivity was performed as described by Barrowcliffe et al, a background region being selected over the great vessels in the abdomen.

**PULMONARY ABSORPTION OF TERBUTALINE**

All subjects were studied at the same time in the morning after a fast of about 10 hours. The smokers were asked not to smoke before the measurements on the study day. To avoid buccal or gastrointestinal absorption of terbutaline, each subject was given a suspension of 5 g of charcoal in 25 ml of water to drink during the two minutes before and after the inhalation of terbutaline. In addition, subjects swallowed 10 g of charcoal dispersed in 50 ml of water one and two hours after the inhalation of terbutaline. They were instructed to swirl the charcoal suspension around in the mouth before swallowing it. The administration of charcoal has been shown to be effective in inhibiting the systemic absorption of terbutaline administered orally.

The absorption of terbutaline from the airways was studied twice in each subject with two different modes of inhalation. The order of the modes of inhalation was randomised, and a washout period of one to four weeks was allowed to elapse between the two parts of the study. On one study day a solution of terbutaline sulphate (2.5 mg/ml) was nebulised with an UltraVent nebuliser and the subject inhaled the aerosol by quiet tidal breathing for three minutes. The duration of inhalation was chosen on the basis of preliminary experiments, so that the dose of terbutaline delivered to the lungs was similar to the dose in two inhalations of dry terbutaline sulphate powder (see below).

On the other study day the subject inhaled two doses (2 x 0.5 mg) of terbutaline sulphate from a powder inhaler (Turbuhaler, AB Draco, Lund, Sweden). Airflow during the inhalation was monitored with a pneumotachograph (Vitalograph Compact) arranged in series with the Turbuhaler and modified for measuring flow during inhalation; peak inspiratory flow was recorded.

Venous blood was sampled from a catheter inserted into a brachial vein before and three, five, eight, 10, 15, 20, 30, 45, 60, 120, and 240 minutes after the inhalation of terbutaline. The samples were centrifuged immediately and plasma was frozen at –18 °C for subsequent measurement of the concentration of terbutaline by gas chromatography and mass spectrometry. After dry powder administration of terbutaline, urine was collected for 36 hours and the total excreted amount of terbutaline was calculated.

**STATISTICAL ANALYSIS**

Individual curves of plasma terbutaline concentration versus time were used to obtain the maximum plasma concentration (Cmax) and the time to maximum plasma concentration (tmax). The rate of appearance of terbutaline in plasma (increase rate) was expressed as the slope of the straight line (best fit) through the origin, time points being used up to and including tmax. Unless otherwise stated, results are presented as means (with standard deviations in parentheses) in the smokers and non-smokers. For the two modes of administration, the variables Cmax, tmax, and rate of increase were analysed first by analysis of variance. We then calculated the mean value after each administration for each patient and compared the means between smokers and non-smokers, using an t test without the assumption of equal variances between the two groups. Corresponding 95% confidence limits were computed. The level of significance was set at p = 0.05.

**Results**

All subjects had normal spirometric values (table 1). The inhaled 99mTc-DTPA showed a uniform distribution throughout the lungs in all subjects (fig 1). Composite curves for the mean values for clearance of 99mTc DTPA from the lungs in smokers and non-smokers are shown in figure 2. In the non-smokers the count rate over the lungs fell monoeXponentially to 50% of the initial value after 71 minutes. The clearance curve from the smokers had a steep initial slope, so that 50% of the initial count rate was reached after 21 minutes.

Concentrations of terbutaline increased much faster in the smokers than in the non-smokers after inhalation of nebulised terbutaline.
butaline or dry powder (fig 2). The Cmax values were nearly twice as high in the smokers as in the non-smokers (table 2), the difference being 9.6 (confidence interval (CI) 6.6–18.7) nmol/l; p < 0.05. The Tmax in the smokers was about one third of that in the non-smokers, the difference being 32 (CI 19–46) minutes; p < 0.0005. The rate of increase in terbutaline plasma concentration was much higher in the smokers than in the non-smokers. The difference was 2.1 (CI 0.8–3.3) nmol/l a minute; p = 0.005.

When the plasma terbutaline concentration curves were compared with respect to the mode of administration, very little difference was noted between inhalation of nebulised terbutaline and dry powder, either in smokers or in non-smokers (fig 1, table 2).

Mean peak inspiratory flow during inhalation of dry terbutaline powder was 59 (range 46–70) l/min in the smokers and 56 (range 44–70) l/min in the non-smokers. The mean (SD) total amount of terbutaline recovered in the urine after powder inhalation was 535 (131) nmol in the smokers and 563 (167) nmol in the non-smokers.

**Discussion**

This study shows that the plasma concentration of terbutaline is substantially higher in smokers than in non-smokers during the first 30 minutes after its inhalation as a nebulised solution or as dry powder.

To ensure delivery of similar amounts of drug to all subjects, the inhalation procedure was standardised and monitored. We collected urine from the subjects after inhalation of dry terbutaline powder and found little difference in urinary excretion of terbutaline over 36 hours between smokers and non-smokers. This shows that the dose of drug delivered to the lungs was similar in the two groups of subjects.

Buccal and gastrointestinal absorption of terbutaline was inhibited by administering charcoal suspension to the subjects. Charcoal given in this manner has been shown to adsorb 97% of an oral dose of terbutaline. The large differences in Cmax and Tmax after the inhalation indicate that absorption of the inhaled drug from the lungs is much faster in smokers than in non-smokers. The smokers in this study were all free from respiratory symptoms and had normal spirometric values. The increased rate of terbutaline absorption is therefore most likely to be due to the effect of tobacco smoke on the physiological barrier functions in the lung.1

The differences in plasma concentration of terbutaline between smokers and non-smokers were seen with both modes of administration. Nebulised terbutaline when inhaled from an UltraVent nebuliser is deposited mainly in the peripheral airways (fig 1), whereas terbutaline inhaled as dry powder is deposited more in the central airways.11 Smoking therefore appears to affect the rate of terbutaline absorption from both central and peripheral airways.

The rationale for administering bronchodilators in aerosol form is to achieve a high local tissue concentration of the drug. The primary site of action of beta, agonists is the bronchial smooth muscle. The drug penetrates the airway mucosa to reach the smooth muscle by diffusion or via the microcirculation. If the penetration of the mucosa is faster in smokers than in non-smokers, this could result in a
Table 2  Mean (SD) maximum plasma concentration (Cmax), time to maximum plasma concentration (tmax), and calculated rate of increase in plasma concentration after inhalation of nebulised terbutaline solution or dry powder in smokers and non-smokers, with 95% confidence limits for the differences between smokers and non-smokers.

<table>
<thead>
<tr>
<th></th>
<th>Smokers (n = 9)</th>
<th>Non-smokers (n = 13)</th>
<th>Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (nmol/l)</td>
<td>Nebulised Powder</td>
<td>23 (16)</td>
<td>21 (9)</td>
</tr>
<tr>
<td>tmax (min)</td>
<td>17 (17)</td>
<td>17 (17)</td>
<td>50 (10)</td>
</tr>
<tr>
<td>Rate of increase (nmol/l/min)</td>
<td>2.6 (2.2)</td>
<td>2.2 (1.4)</td>
<td>0.3 (0.1)</td>
</tr>
</tbody>
</table>

Table 2 continued

Table 2: Mean (SD) maximum plasma concentration (Cmax), time to maximum plasma concentration (tmax), and calculated rate of increase in plasma concentration after inhalation of nebulised terbutaline solution or dry powder in smokers and non-smokers, with 95% confidence limits for the differences between smokers and non-smokers.

<table>
<thead>
<tr>
<th></th>
<th>Smokers (n = 9)</th>
<th>Non-smokers (n = 13)</th>
<th>Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (nmol/l)</td>
<td>Nebulised Powder</td>
<td>23 (16)</td>
<td>21 (9)</td>
</tr>
<tr>
<td>tmax (min)</td>
<td>17 (17)</td>
<td>17 (17)</td>
<td>50 (10)</td>
</tr>
<tr>
<td>Rate of increase (nmol/l/min)</td>
<td>2.6 (2.2)</td>
<td>2.2 (1.4)</td>
<td>0.3 (0.1)</td>
</tr>
</tbody>
</table>

faster onset of the therapeutic action in smokers.

The peak plasma concentration of terbutaline was much higher in smokers than in non-smokers. The relation between bronchodi lation and plasma concentration after inhalation has been studied in asthmatic subjects by van den Berg, who found that a clearly detectable airway effect was associated with a peak plasma concentration of about 2 nmol/l. The therapeutic range of terbutaline plasma concentration for systemic treatment is 10–25 nmol/l. The mean peak plasma concentration found in the non-smokers in this study was below the lower limit of the therapeutic range for systemic treatment, indicating that little therapeutic effect may be expected from recirculating drug. The plasma concentrations in the smokers during the first hour after inhalation of terbutaline were higher, and recirculating drug could therefore contribute to bronchodilation in smokers. Systemic side effects after inhalation of terbutaline may also be more common in smoking than in non-smoking subjects. Side effects were not assessed in this study.

The difference in the rate of increase in plasma concentration indicates that terbutaline is removed from the lungs at a higher rate in smokers than in non-smokers. To the extent that this reflects a difference in the rate of decline in terbutaline concentration at the site of action, it suggests that the duration of the therapeutic effect may be shorter in smoking than in non-smoking subjects. This could not be tested in this study of normal subjects.

The influence of lung disease on the pulmonary absorption of terbutaline is largely unknown, but some inference can be made from studies of the pulmonary clearance of 99mTc-DTPA. Most of the available evidence suggests that there is no great increase in the alveolarcapillary transfer of 99mTc-DTPA in non-smokers with stable asthma. Increased lung volume and ventilation with a large tidal volume, as occurs during exercise, augment the pulmonary clearance of 99mTc-DTPA. This may be relevant to bronchodilator aerosol treatment of patients with asthma with hyperinflation or exercise induced asthma. Increased pulmonary clearance of 99mTc-DTPA has been reported in many interstitial lung diseases, such as sarcoidosis. Airflow obstruction is common in sarcoidosis, and patients treated with inhaled terbutaline may have a faster pulmonary absorption of the drug than normal subjects.

We have shown that the pulmonary absorption of terbutaline is much faster in smokers than in non-smokers. This may be relevant to its therapeutic effect, by giving a faster onset of action and a shorter duration of the therapeutic effect in smokers than in non-smokers. Further studies of the relation between smoking habits and the efficacy of aerosol bronchodilator treatment are warranted.

We thank Dr Anders Källen, AB Draco, for statistical advice. The study was supported by grants from the Swedish Medical Research Council (No.20872), the Swedish National Association against Chest and Heart Diseases, the Swedish Work Environment Fund, and AB Procorida Nova.